Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset

BACKGROUND AND PURPOSE: Antiplatelets (APs) may increase the risk of symptomatic intracerebral hemorrhage (ICH) following intravenous thrombolysis after ischemic stroke. - METHODS: We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and re...

Full description

Saved in:
Bibliographic Details
Main Authors: Diedler, Jennifer (Author) , Ahmed, Niaz (Author) , Sykora, Marek (Author) , Uyttenboogaart, Maarten (Author) , Overgaard, Karsten (Author) , Luijckx, Gert-Jan (Author) , Soinne, Lauri (Author) , Ford, Gary A. (Author) , Lees, Kennedy R. (Author) , Wahlgren, Nils (Author) , Ringleb, Peter A. (Author)
Format: Article (Journal)
Language:English
Published: 7 January 2010
In: Stroke
Year: 2010, Volume: 41, Issue: 2, Pages: 288-294
ISSN:1524-4628
DOI:10.1161/STROKEAHA.109.559724
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1161/STROKEAHA.109.559724
Verlag, lizenzpflichtig, Volltext: https://www.ahajournals.org/doi/10.1161/STROKEAHA.109.559724
Get full text
Author Notes:Jennifer Diedler, MD, Niaz Ahmed, MD, PhD, Marek Sykora, MD, Maarten Uyttenboogaart, MD, Karsten Overgaard, MD, Gert-Jan Luijckx, MD, Lauri Soinne, MD, Gary A. Ford, FRCP, Kennedy R. Lees, MD, FRCP, Nils Wahlgren, MD, PhD, and Peter Ringleb, MD

MARC

LEADER 00000caa a2200000 c 4500
001 1881515508
003 DE-627
005 20240311115515.0
007 cr uuu---uuuuu
008 240223s2010 xx |||||o 00| ||eng c
024 7 |a 10.1161/STROKEAHA.109.559724  |2 doi 
035 |a (DE-627)1881515508 
035 |a (DE-599)KXP1881515508 
035 |a (OCoLC)1425872624 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Diedler, Jennifer  |d 1977-  |e VerfasserIn  |0 (DE-588)129864528  |0 (DE-627)482365676  |0 (DE-576)188965483  |4 aut 
245 1 0 |a Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset  |c Jennifer Diedler, MD, Niaz Ahmed, MD, PhD, Marek Sykora, MD, Maarten Uyttenboogaart, MD, Karsten Overgaard, MD, Gert-Jan Luijckx, MD, Lauri Soinne, MD, Gary A. Ford, FRCP, Kennedy R. Lees, MD, FRCP, Nils Wahlgren, MD, PhD, and Peter Ringleb, MD 
264 1 |c 7 January 2010 
300 |b Illustrationen 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 23.02.2024 
520 |a BACKGROUND AND PURPOSE: Antiplatelets (APs) may increase the risk of symptomatic intracerebral hemorrhage (ICH) following intravenous thrombolysis after ischemic stroke. - METHODS: We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR). Outcome measures of univariable and multivariable analyses included symptomatic ICH (SICH) per SITS Monitoring Study (SITS-MOST [deterioration in National Institutes of Health Stroke Scale >or=4 plus ICH type 2 within 24 hours]), per European Cooperative Acute Stroke Study II (ECASS II [deterioration in National Institutes of Health Stroke Scale >or=4 plus any ICH]), functional outcome at 3 months and mortality. - RESULTS: A total of 3782 (31.9%) patients had received 1 or 2 AP drugs at baseline: 3016 (25.4%) acetylsalicylic acid (ASA), 243 (2.0%) clopidogrel, 175 (1.5%) ASA and dipyridamole, 151 (1.3%) ASA and clopidogrel, and 197 (1.7%) others. Patients receiving APs were 5 years older and had more risk factors than AP naïve patients. Incidences of SICH per SITS-MOST (ECASS II respectively) were as follows: 1.1% (4.1%) AP naïve, 2.5% (6.2%) any AP, 2.5% (5.9%) ASA, 1.7% (4.2%) clopidogrel, 2.3% (5.9%) ASA and dipyridamole, and 4.1% (13.4%) ASA and clopidogrel. In multivariable analyses, the combination of ASA and clopidogrel was associated with increased risk for SICH per ECASS II (odds ratio, 2.11; 95% CI, 1.29 to 3.45; P=0.003). However, we found no significant increase in the risk for mortality or poor functional outcome, irrespective of the AP subgroup or SICH definition. - CONCLUSIONS: The absolute excess of SICH of 1.4% (2.1%) in the pooled AP group is small compared with the benefit of thrombolysis seen in randomized trials. Although caution is warranted in patients receiving the combination of ASA and clopidogrel, AP treatment should not be considered a contraindication to thrombolysis. 
650 4 |a Acute Disease 
650 4 |a Adolescent 
650 4 |a Adult 
650 4 |a Aged 
650 4 |a Aged, 80 and over 
650 4 |a Aspirin 
650 4 |a Brain Ischemia 
650 4 |a Cerebral Hemorrhage 
650 4 |a Clopidogrel 
650 4 |a Contraindications 
650 4 |a Dipyridamole 
650 4 |a Drug Incompatibility 
650 4 |a Drug Therapy, Combination 
650 4 |a Drug-Related Side Effects and Adverse Reactions 
650 4 |a Female 
650 4 |a Fibrinolytic Agents 
650 4 |a Humans 
650 4 |a Incidence 
650 4 |a Injections, Intravenous 
650 4 |a Male 
650 4 |a Middle Aged 
650 4 |a Platelet Aggregation Inhibitors 
650 4 |a Risk Assessment 
650 4 |a Stroke 
650 4 |a Ticlopidine 
650 4 |a Tissue Plasminogen Activator 
650 4 |a Treatment Outcome 
650 4 |a Young Adult 
700 1 |a Ahmed, Niaz  |e VerfasserIn  |4 aut 
700 1 |a Sykora, Marek  |e VerfasserIn  |0 (DE-588)1050283503  |0 (DE-627)783780796  |0 (DE-576)383589304  |4 aut 
700 1 |a Uyttenboogaart, Maarten  |e VerfasserIn  |4 aut 
700 1 |a Overgaard, Karsten  |e VerfasserIn  |4 aut 
700 1 |a Luijckx, Gert-Jan  |e VerfasserIn  |4 aut 
700 1 |a Soinne, Lauri  |e VerfasserIn  |4 aut 
700 1 |a Ford, Gary A.  |e VerfasserIn  |4 aut 
700 1 |a Lees, Kennedy R.  |e VerfasserIn  |4 aut 
700 1 |a Wahlgren, Nils  |e VerfasserIn  |0 (DE-588)1062499476  |0 (DE-627)805306579  |0 (DE-576)41827813X  |4 aut 
700 1 |a Ringleb, Peter A.  |e VerfasserIn  |0 (DE-588)1032676175  |0 (DE-627)73863364X  |0 (DE-576)172917743  |4 aut 
773 0 8 |i Enthalten in  |t Stroke  |d New York, NY : Association, 1970  |g 41(2010), 2 vom: Feb., Seite 288-294  |h Online-Ressource  |w (DE-627)266879985  |w (DE-600)1467823-8  |w (DE-576)075145731  |x 1524-4628  |7 nnas  |a Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset 
773 1 8 |g volume:41  |g year:2010  |g number:2  |g month:02  |g pages:288-294  |g extent:7  |a Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset 
856 4 0 |u https://doi.org/10.1161/STROKEAHA.109.559724  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.ahajournals.org/doi/10.1161/STROKEAHA.109.559724  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20240223 
993 |a Article 
994 |a 2010 
998 |g 1032676175  |a Ringleb, Peter A.  |m 1032676175:Ringleb, Peter A.  |d 910000  |d 911100  |e 910000PR1032676175  |e 911100PR1032676175  |k 0/910000/  |k 1/910000/911100/  |p 11  |y j 
998 |g 1050283503  |a Sykora, Marek  |m 1050283503:Sykora, Marek  |d 910000  |d 911100  |e 910000PS1050283503  |e 911100PS1050283503  |k 0/910000/  |k 1/910000/911100/  |p 3 
998 |g 129864528  |a Diedler, Jennifer  |m 129864528:Diedler, Jennifer  |d 910000  |d 911100  |e 910000PD129864528  |e 911100PD129864528  |k 0/910000/  |k 1/910000/911100/  |p 1  |x j 
999 |a KXP-PPN1881515508  |e 4490440855 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Jennifer Diedler, MD, Niaz Ahmed, MD, PhD, Marek Sykora, MD, Maarten Uyttenboogaart, MD, Karsten Overgaard, MD, Gert-Jan Luijckx, MD, Lauri Soinne, MD, Gary A. Ford, FRCP, Kennedy R. Lees, MD, FRCP, Nils Wahlgren, MD, PhD, and Peter Ringleb, MD"]},"recId":"1881515508","note":["Gesehen am 23.02.2024"],"origin":[{"dateIssuedKey":"2010","dateIssuedDisp":"7 January 2010"}],"id":{"eki":["1881515508"],"doi":["10.1161/STROKEAHA.109.559724"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"person":[{"given":"Jennifer","family":"Diedler","display":"Diedler, Jennifer","role":"aut"},{"family":"Ahmed","display":"Ahmed, Niaz","given":"Niaz","role":"aut"},{"role":"aut","family":"Sykora","display":"Sykora, Marek","given":"Marek"},{"given":"Maarten","family":"Uyttenboogaart","display":"Uyttenboogaart, Maarten","role":"aut"},{"display":"Overgaard, Karsten","family":"Overgaard","given":"Karsten","role":"aut"},{"role":"aut","family":"Luijckx","display":"Luijckx, Gert-Jan","given":"Gert-Jan"},{"role":"aut","display":"Soinne, Lauri","family":"Soinne","given":"Lauri"},{"role":"aut","display":"Ford, Gary A.","family":"Ford","given":"Gary A."},{"role":"aut","given":"Kennedy R.","display":"Lees, Kennedy R.","family":"Lees"},{"role":"aut","family":"Wahlgren","display":"Wahlgren, Nils","given":"Nils"},{"role":"aut","given":"Peter A.","display":"Ringleb, Peter A.","family":"Ringleb"}],"title":[{"title_sort":"Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset","title":"Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset"}],"physDesc":[{"extent":"7 S.","noteIll":"Illustrationen"}],"relHost":[{"disp":"Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onsetStroke","note":["Gesehen am 29.06.04"],"pubHistory":["1.1970 -"],"recId":"266879985","origin":[{"publisherPlace":"New York, NY ; Philadelphia, Pa.","dateIssuedDisp":"1970-","dateIssuedKey":"1970","publisher":"Association ; Lippincott Williams & Wilkins"}],"id":{"zdb":["1467823-8"],"issn":["1524-4628"],"eki":["266879985"]},"corporate":[{"display":"American Heart Association","role":"isb"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"part":{"year":"2010","extent":"7","issue":"2","volume":"41","pages":"288-294","text":"41(2010), 2 vom: Feb., Seite 288-294"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"journal of the American Heart Association","title":"Stroke","title_sort":"Stroke"}]}]} 
SRT |a DIEDLERJENSAFETYOFIN7201